GLP-1s, menopause, hormone-adjacent skin changes, and aesthetic claims that need evidence boundaries.
A clinical evaluation of lipotropic MIC-B12 injections, examining the evidence for weight-loss claims, metabolic pathways, and safety profiles from public database…
An evidence-based clinical review of NAD+ IV therapy, analyzing the 2025 FDA Class I recall of GenoGenix lots, endotoxin contamination risks, and human clinical trial…
Semaglutide's key US patent runs to late 2031 and tirzepatide's to early 2036. We read the FDA Orange Book to show when generic GLP-1 weight-loss drugs can actually…
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…
Vaginal laser and RF devices (MonaLisa Touch, ThermiVa) are FDA-cleared for gynecology - not for menopause GSM. The 2018 FDA warning, the evidence, and first-line…
A staged cost breakdown for facial rejuvenation after GLP-1 or other weight loss — topicals, fillers, biostimulators, fat grafting, skin tightening devices, and surgery.…
Perimenopause accelerates facial aging through estrogen-driven collagen loss — up to 30% in the first five years after menopause.
Profhilo is an injectable hyaluronic acid bioremodeller that stimulates collagen and elastin without adding volume.
A consult framework for GLP-1 facial volume loss, including weight stability, staged filler or biostimulator plans, overcorrection risk, and surgical referral boundaries.
GLP-1 drugs drive major weight loss but leave excess skin, stubborn fat, and facial volume loss. Evidence-based guide to surgical and non-surgical contouring options…